Preferred Label : Anti-DLL3 Antibody-drug Conjugate FZ-AD005;
NCIt synonyms : ADC FZ-AD005; Anti-DLL3 ADC FZ-AD005; FZ-A038/DXd ADC FZ-AD005;
NCIt definition : An antibody-drug conjugate (ADC) composed of FZ-A038, a monoclonal antibody directed
against the tumor-associated antigen (TAA) delta-like protein 3 (DLL3), conjugated,
via a valine-alanine (Val-Ala) dipeptide linker, to the cytotoxic DNA topoisomerase
I inhibitor and exatecan derivative DXd (MAAA-1181a; MAAA-1181), with potential antineoplastic
activity. Upon administration, anti-DLL3 ADC FZ-AD005 targets and binds to DLL3-expressing
tumor cells. Upon binding and internalization, DXd is released. DXd inhibits DNA topoisomerase
I activity, thereby inhibiting DNA replication and resulting in cell cycle arrest
and tumor cell apoptosis. This inhibits the proliferation of DLL3-expressing tumor
cells. FZ-AD005 is also able to induce a bystander effect on neighboring cells in
the tumor environment. This further inhibits the proliferation of tumor cells. In
addition, FZ-AD005 is Fc-silenced, which may prevent Fc gamma receptor (FcgR)-mediated
toxicities. DLL3, a Notch pathway protein, is overexpressed on a variety of cancer
cell types. It plays a key role in embryonic development, tumor initiation and proliferation.;
Molecule name : FZ AD005; FZ-AD005;
Origin ID : C216083;
concept_is_in_subset
- has_target
